IL-6 signaling orchestrates proteolytic hubs MuRF1 and Atrogin-1 in NSCLC induced sarcopenia

Gautam Kumar1,2, Shailza Singh1,2

  • 1Systems Medicine Laboratory, BRIC- National Centre for Cell Science, NCCS Complex, Ganeshkhind, Pune, India.

Frontiers in Immunology
|August 18, 2026
PubMed

Insights

Non-small cell lung cancer (NSCLC) causes muscle wasting (sarcopenia) through complex signaling. Key muscle breakdown regulators, IL-6 and SMAD2/3, identified as therapeutic targets to combat this debilitating condition.

Area of Science:

  • Oncology
  • Systems Biology
  • Muscle Physiology

Background:

  • Non-small cell lung cancer (NSCLC) is strongly linked to sarcopenia, a severe muscle-wasting condition.
  • Tumor-muscle cross-talk involves complex inflammatory, anabolic, catabolic, and proteolytic pathways.
  • Understanding these pathways is crucial for developing effective treatments for NSCLC-associated sarcopenia.

Purpose of the Study:

  • To reconstruct and model the signaling network driving NSCLC-associated sarcopenia.
  • To identify key regulatory control points and therapeutic targets within this network.
  • To experimentally validate the model's predictions regarding muscle protein breakdown.

Main Methods:

  • Reconstruction of a comprehensive signaling network.
  • Development of a mechanistic mathematical model using ordinary differential equations.
  • Flux analysis, crosstalk analysis, and principal component analysis.
  • Experimental validation using immunofluorescence-based confocal microscopy.

Main Results:

  • Cytoplasmic IL-6 export and SMAD2/3-mediated induction of MuRF1 and Atrogin-1 are major control points for muscle protein breakdown.
  • Proteolytic regulators MuRF1 and Atrogin-1 act as central hubs integrating inflammatory and stress signals.
  • The IL-6/STAT3, myostatin/SMAD, and FOXO/NF-κB pathways converge on MuRF1 and Atrogin-1, governing sarcopenic progression.
  • Experimental validation confirmed increased expression and altered localization of ubiquitin ligases in co-cultured cells.

Conclusions:

  • A systems-level framework identifies key therapeutic targets for NSCLC-associated sarcopenia.
  • Combined strategies blocking the IL-6/STAT3-myostatin/SMAD-FOXO1/3-MuRF1/Atrogin-1 axis are promising.
  • This approach transforms broad observations of inflammation into ranked therapeutic strategies.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...